Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose vs standard-dose quadrivalent influenza vaccine in adults 65+
NCT04137887Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Nov 2019
- Primary completion
- May 2020
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of influenza vaccine (quadrivalent, high-dose) in influenza, sponsored by Sanofi. Started Nov 2019; status: terminated.
02
Drugs
influenza vaccine (quadrivalent, high-dose)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04137887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04137887.